BEIJING, July 26, 2017 -- ChinaCache International Holdings Ltd. ("ChinaCache" or the "Company") (Nasdaq:CCIH), a leading total solutions provider of Internet content and application delivery services in China, today announced that its independent director, Mr. Ya-Qin Zhang, has submitted his resignation from the board of directors of the Company (the “Board”), effective July 26, 2017. Mr. Zhang’s resignation was not due to any disagreement with the Company regarding its business, finance, accounting or any other matters. Prior to his resignation, Mr. Zhang also served as a member of the Compensation Committee and the Nominating and Corporate Governance Committee of the Board. The Board thanks him for his service for the past years. Upon the effectiveness of Mr. Zhang’s resignation, the Board of ChinaCache will consist of five directors, including three independent directors.
About ChinaCache International Holdings Ltd.
ChinaCache International Holdings Ltd. (Nasdaq:CCIH) is a leading total solutions provider of Internet content and application delivery services in China. As a carrier-neutral service provider, ChinaCache's network in China is interconnected with networks operated by all telecom carriers, major non-carriers and local Internet service providers. With more than a decade of experience in developing solutions tailored to China's complex Internet infrastructure, ChinaCache is a partner of choice for businesses, government agencies and other enterprises to enhance the reliability and scalability of online services and applications and improve end-user experience. For more information on ChinaCache, please visit ir.chinacache.com.
For investor and media inquiries please contact: Investor Relations Department ChinaCache International Holdings Tel: +86 10 6408 5307 Email: [email protected] Mr. Ross Warner The Piacente Group | Investor Relations Tel: +86 10 5730-6200 Email: [email protected] Ms. Brandi Piacente The Piacente Group | Investor Relations Tel: +1 212-481 2050 Email: [email protected]


AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program
FDA Approves Mitapivat for Anemia in Thalassemia Patients
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 



